红日药业：5月19日召开业绩说明会，投资者参与

Core Viewpoint - Hongri Pharmaceutical (300026) held a performance briefing on May 19, 2025, to discuss its business developments and future plans [1]. Business Overview - The company's business segments include traditional Chinese medicine formula granules, finished drugs, medical devices, raw and auxiliary materials, healthcare services, and smart supply chain for medical devices [2]. - The company is focusing on enhancing its core competitiveness and operational efficiency to solidify its intrinsic value [4][5]. Product Development - The company is actively engaged in the research and development of innovative and improved drugs, generic drugs, and medical devices, with a focus on core competitive products [5]. - The "Modern Chinese Medicine New Quality Production Capacity Technology Innovation Project" initiated in Tianjin aims to upgrade the production capacity and quality stability of the blood-bijing injection [5]. Financial Performance - In Q1 2025, the company reported a main revenue of 1.393 billion yuan, a year-on-year decrease of 4.82%, while the net profit attributable to shareholders was 60.33 million yuan, an increase of 3.8% [22]. - The company has a debt ratio of 19.65% and a gross profit margin of 51.89% [22]. Market Strategy - The company plans to enhance its domestic market presence for medical devices by optimizing its business model and integrating effective market resources [16]. - The company is committed to continuous innovation and development in response to market demands and policy changes, particularly in the context of national medical insurance adjustments [21][22]. Shareholder Relations - The company confirmed that if the controlling shareholder has any plans for shareholding increase, it will comply with legal disclosure requirements [3]. - The company is focused on maintaining stable control and operational normalcy amidst shareholder disputes [12].